Beta-Amyloid, a peptide derived from amyloid precursor protein (APP), is the major component of amyloid plaques that define Alzheimer’s disease (AD) pathology. Accumulation of beta-amyloid aggregates—ranging from soluble oligomers to insoluble fibrils—disrupts synaptic signaling, triggers neuroinflammation, and accelerates tau pathology, making beta-amyloid a validated target for neurodegeneration research. The amyloid cascade hypothesis highlights beta-amyloid as a driver of disease progression, positioning it at the center of Alzheimer’s diagnostics, therapeutic antibody development, and biomarker discovery. Recent advances in beta-amyloid monoclonal antibodies, including aducanumab, lecanemab, and donanemab, demonstrate that targeted beta-amyloid clearance can reduce amyloid burden and modestly slow cognitive decline. These results emphasize the importance of sensitive and specific research tools for investigating beta-amyloid biology, immunotherapy efficacy, and disease mechanisms. Catalina provides high-quality beta-amyloid antibodies with reliable performance and reproducibility, supporting cutting-edge research in Alzheimer’s disease pathogenesis, drug development, and neuroimmunology.